Using Histology to personalize Patient Care - Blake Richards, CEO of Elucid

What’s the difference between Elucid’s technology and what many other diagnostic tools seek to do?

Blake Richards, CEO, Elucid, explains, “Our high-water mark, what we compare ourselves to is actual biology, actual tissue that’s been removed and physically annotated by pathologists to determine true histopathology. Other tools use as their high-water mark what a physician is able to discern from that routine CTA.”

Elucid seeks to go beyond what a human eye is capable of doing to have a better method to accurately predict the risk of heart attack or stroke enabling a more personalized treatment plan for the patient.

Learn how the Elucid platform uses histology to personalize patient care.